Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open- label, phase 3 trial - The Lancet
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial - European Journal of Cancer
Avastin - FDA prescribing information, side effects and uses
Avastin's breast cancer use to continue in Europe | Pharmafile
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial - The Lancet Oncology
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study - The Lancet Oncology
Genentech warns of fake Avastin
PLOS ONE: A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial - The Lancet Gastroenterology & Hepatology
PLOS ONE: A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard
More Medicare Musings: Why Lucentis is Worth the Price Tag - Eyedolatry
S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study -
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial - The Lancet Respiratory
NHS wins legal fight against pharma firms over sight-loss drug | NHS | The Guardian
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial - The Lancet Oncology
Immunotherapy Regimen Approved for Hepatocellular Carcinoma - MPR
Avastin disappoints against ovarian cancer | KCBY
ICD-9/10 codes to define serious adverse events for Bevacizumab based... | Download Scientific Diagram
File:Bevacizumab label 01.jpg - wikidoc
Italy free to reimburse off-label Avastin, rules EU court -
PDF] Off-label use of bevacizumab for wet age-related macular degeneration in Europe | Semantic Scholar
avastin - Diabetic Retinopathy
BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer - Journal of Thoracic Oncology
Avastin approval for breast cancer pulled | CBC News